Published in Hamostaseologie on January 01, 2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol (2009) 1.05
Effect of Alzheimer caregiving on circulating levels of C-reactive protein and other biomarkers relevant to cardiovascular disease risk: a longitudinal study. Gerontology (2011) 0.90
Aptamers as therapeutics in cardiovascular diseases. Curr Med Chem (2011) 0.84
Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun (2015) 0.84
Is ABO blood group truly a risk factor for thrombosis and adverse outcomes? World J Cardiol (2014) 0.81
Ways of coping and biomarkers of an increased atherothrombotic cardiovascular disease risk in elderly individuals. Cardiovasc Psychiatry Neurol (2012) 0.79
Differential surface activation of the A1 domain of von Willebrand factor. Biointerphases (2016) 0.78
Von Willebrand factor and oxidative stress parameters in acute coronary syndromes. Oxid Med Cell Longev (2011) 0.77
Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. Lupus Sci Med (2016) 0.75
Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Exp Ther Med (2015) 0.75
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet (2007) 2.50
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost (2006) 2.22
Massive pulmonary embolism leading to cardiac arrest is associated with consumptive coagulopathy presenting as disseminated intravascular coagulation. J Thromb Haemost (2010) 1.60
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther (1999) 1.50
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost (2012) 1.48
Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther (2000) 1.46
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood (2000) 1.45
Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost (2006) 1.43
Studies on the effect of short-term oral dihydroergotamine and troxerutin in patients with varicose veins. Clin Pharmacol Ther (1994) 1.40
Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost (2007) 1.10
Heparin blunts endotoxin-induced coagulation activation. Circulation (2000) 1.09
Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost (2006) 1.09
Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion (2001) 1.05
Effects of low dose endotoxemia on endothelial progenitor cells in humans. Atherosclerosis (2007) 1.02
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.01
Sex differences in HAART-associated dyslipidaemia. AIDS (2001) 1.00
Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol (1996) 1.00
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost (2009) 0.97
Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine (2008) 0.95
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis (2008) 0.94
Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost (2009) 0.93
Sex differences in the association between albumin and all-cause and vascular mortality. Eur J Clin Invest (2009) 0.93
Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab (1997) 0.92
Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost (1999) 0.91
Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost (2000) 0.91
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost (2012) 0.89
Lepirudin blunts endotoxin-induced coagulation activation. Blood (2000) 0.89
Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation (1997) 0.88
Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost (2001) 0.87
Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens (1999) 0.86
Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol (1998) 0.86
Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol (1999) 0.85
Impaired platelet function among platelet donors. Thromb Haemost (2001) 0.83
High levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol (2001) 0.83
Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2001) 0.83
Plasma levels of activated factor VII decrease during the menstrual cycle. Thromb Haemost (1998) 0.83
Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man. Atherosclerosis (2000) 0.83
Direct evidence for an increase in thrombopoiesis after liver transplantation. Eur J Clin Invest (1998) 0.82
Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Int J Immunopathol Pharmacol (2007) 0.82
The effect of plasma removal from apheresis platelet concentrates on platelet function. Vox Sang (2011) 0.81
Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis (2000) 0.80
Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int J Immunopathol Pharmacol (2009) 0.80
Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats. Food Chem Toxicol (2008) 0.79
Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol (2000) 0.79
Effects of endothelin-1 (ET-1) on ocular hemodynamics. Curr Eye Res (1997) 0.79
Endotoxemia enhances circulating endothelial cells in humans. J Thromb Haemost (2006) 0.79
Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol (1996) 0.79
Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J (2009) 0.78
Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin. Transfusion (1998) 0.78
Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer CoaguCheck Plus in various clinical settings. Thromb Res (1997) 0.78
A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery. Clin Exp Immunol (2015) 0.78
Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrinolysis. J Hum Hypertens (2012) 0.78
Sex differences in circulating P-selectin, E-selectin and thrombomodulin. Br J Haematol (1996) 0.78
Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb Res (1997) 0.78
Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost (2004) 0.78
Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans. Eur J Clin Invest (2003) 0.78
Man, mouse and Duffy genotype-phenotype-specific pharmacokinetics of monocyte chemotactic protein-1. Transfus Med (2004) 0.78
Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation. Thromb Res (2000) 0.77
Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther (2005) 0.77
Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med (2001) 0.77
Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS (1999) 0.77
Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. Int J Clin Pharmacol Ther (2005) 0.77
Regional cortical development in very low birth weight infants with normal neurodevelopmental outcome assessed by 3D-ultrasound. J Perinatol (2012) 0.77
Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. Atherosclerosis (2001) 0.77
Elevated numbers of reticulated platelets in hyperthyroidism: direct evidence for an increase of thrombopoiesis. Br J Haematol (1998) 0.76
Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol (2001) 0.76
Potential biomarkers of an exaggerated response to endotoxemia. Biomarkers (2007) 0.76
Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion (1998) 0.76
Dexamethasone downregulates L-selectin in vitro and in vivo. Circulation (1998) 0.75
Soluble P-selectin in diabetes. Thromb Haemost (1999) 0.75
Granulocyte colony-stimulating factor and cytokine release. Clin Pharmacol Ther (2000) 0.75
Evidence against an effect of endothelin-1 on blood coagulation, fibrinolysis, and endothelial cell integrity in healthy men. Arterioscler Thromb Vasc Biol (1997) 0.75
Heparin lowers plasma levels of activated factor VII. Br J Haematol (1999) 0.75
Putative role of adhesion molecules in metabolic disorders. Horm Metab Res (1997) 0.75
Surrogate markers to monitor efficacy of anticoagulants or antiplatelet drugs in atrial fibrillation. Eur Heart J (2002) 0.75
Effects of indomethacin on the L-selectin expression in humans. Scand J Immunol (2001) 0.75
Effects of nitroglycerin and sodium nitroprusside on endexpiratory concentrations of nitric oxide in healthy humans. Life Sci (1998) 0.75
The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. Int J Clin Pharmacol Ther (2008) 0.75
Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway. Thromb Res (1997) 0.75
Does phosphodiesterase III inhibition reverse the cardiodepressive effects of propofol? Anesth Analg (1997) 0.75
The proportion of reticulated platelets is higher in bone marrow than in peripheral blood in haematological patients. Eur J Haematol (1999) 0.75
Delayed effect of desmopressin on circulating neutrophils and monocytes. Br J Haematol (1996) 0.75
Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in Type II diabetic patients suffering from microalbuminuria. Diabetologia (1998) 0.75
Immunoglobulin administration to fetuses with anemia due to alloimmunization to D. Transfusion (2000) 0.75
Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol (2003) 0.75
A new flow cytometric method for simultaneous measurement of residual platelets and RBCs in plasma: validation and application for QC. Transfusion (2001) 0.75
Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost (2006) 0.75
Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.75
The platelet alpha2-integrin (GPIa) nucleotide-807 polymorphism is not associated with a risk for maternal-fetal human platelet antigen-5 incompatibility. Ann Hematol (2000) 0.75
Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion (1999) 0.75
Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation. Clin Pharmacol Ther (2007) 0.75
Safety issues of plateletpheresis: comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil-platelet aggregates. Transfusion (1999) 0.75
The association of the Thr715Pro P-selectin genotype with levels of P-selectin in platelet concentrates. Vox Sang (2014) 0.75
Thrombopoiesis is increased in hyperthyroidism. J Clin Endocrinol Metab (1998) 0.75